Shadman M: Diagnosis and treatment of chronic lymphocytic leukemia: A review. JAMA. 329:918–932. 2023.PubMed/NCBI View Article : Google Scholar

Hampel PJ and Parikh SA: Correction: Chronic lymphocytic leukemia treatment algorithm 2022. Blood Cancer J. 12(172)2022.PubMed/NCBI View Article : Google Scholar

Chen SS and Chiorazzi N: Functional consequences of inhibition of Bruton's tyrosine kinase by ibrutinib in chronic lymphocytic leukemia. Hematol Oncol. 41 (Suppl 1):S119–S128. 2023.PubMed/NCBI View Article : Google Scholar

Wen T, Wang J, Shi Y, Qian H and Liu P: Inhibitors targeting Bruton's tyrosine kinase in cancers: Drug development advances. Leukemia. 35:312–332. 2021.PubMed/NCBI View Article : Google Scholar

Rey-Barroso J, Munaretto A, Rouquié N, Mougel A, Chassan M, Gadat S, Dewingle O, Poincloux R, Cadot S, Ysebaert L, et al: Lymphocyte migration and retention properties affected by ibrutinib in chronic lymphocytic leukemia. Haematologica. 109:809–823. 2024.PubMed/NCBI View Article : Google Scholar

Song Y, Zhou K, Yang S, Hu J, Zou D, Gao S, Pan L, Wang T, Yang H, Zhang H, et al: Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma. Invest New Drugs. 41:606–616. 2023.PubMed/NCBI View Article : Google Scholar

Rozkiewicz D, Hermanowicz JM, Kwiatkowska I, Krupa A and Pawlak D: Bruton's tyrosine kinase inhibitors (BTKIs): Review of preclinical studies and evaluation of clinical trials. Molecules. 28(2400)2023.PubMed/NCBI View Article : Google Scholar

Dhillon S: Tirabrutinib: First approval. Drugs. 80:835–840. 2020.PubMed/NCBI View Article : Google Scholar

Seymour C: FDA Approves Pirtobrutinib for Previously Treated CLL/SLL. https://www.onclive.com/view/fda-approves-pirtobrutinib-for-previously-treated-cll-sll. Available on February 21, 2024.

Bennett R, Anderson MA and Seymour JF: Unresolved questions in selection of therapies for treatment-naïve chronic lymphocytic leukemia. J Hematol Oncol. 16(72)2023.PubMed/NCBI View Article : Google Scholar

Alu A, Lei H, Han X, Wei Y and Wei X: BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: Mechanisms and clinical studies. J Hematol Oncol. 15(138)2022.PubMed/NCBI View Article : Google Scholar

Nakhoda S, Vistarop A and Wang YL: Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma. Br J Haematol. 200:137–149. 2023.PubMed/NCBI View Article : Google Scholar

Xu W, Zhou K, Wang T, Yang S, Liu L, Hu Y, Zhang W, Ding K, Zhou J, Gao S, et al: Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi-center, single-arm, open-label, phase 2 study. Am J Hematol. 98:571–579. 2023.PubMed/NCBI View Article : Google Scholar

Cao XX, Jin J, Fu CC, Yi SH, Zhao WL, Sun ZM, Yang W, Li DJ, Cui GH, Hu JD, et al: Evaluation of orelabrutinib monotherapy in patients with relapsed or refractory Waldenstrom's macroglobulinemia in a single-arm, multicenter, open-label, phase 2 study. EClinicalMedicine. 52(101682)2022.PubMed/NCBI View Article : Google Scholar

Kaptein A, de Bruin G, Emmelot-van Hoek M, van de Kar B, de Jong A, Gulrajani M, Demont D, Covey T, Mittag D and Barf T: Potency and selectivity of BTK inhibitors in clinical development for B-cell malignancies. CLL: Therapy, excluding transplantation: Poster I. Blood. 132 (Suppl 1)(S1871)2018.

Robak T, Witkowska M and Smolewski P: The role of Bruton's kinase inhibitors in chronic lymphocytic leukemia: Current status and future directions. Cancers (Basel). 14(771)2022.PubMed/NCBI View Article : Google Scholar

Berglöf A, Hamasy A, Meinke S, Palma M, Krstic A, Månsson R, Kimby E, Österborg A and Smith CI: Targets for ibrutinib beyond B cell malignancies. Scand J Immunol. 82:208–217. 2015.PubMed/NCBI View Article : Google Scholar

Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y, Hessler JD, Liu TM, Chang BY, Larkin KM, et al: Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 122:2539–2549. 2013.PubMed/NCBI View Article : Google Scholar

Montoya S and Thompson MC: Non-covalent bruton's tyrosine kinase inhibitors in the treatment of chronic lymphocytic leukemia. Cancers (Basel). 15(3648)2023.PubMed/NCBI View Article : Google Scholar

Li L, Su M, Lu W, Song H, Liu J, Wen X, Suo Y, Qi J, Luo X, Zhou YB, et al: Triazine-based covalent DNA-encoded libraries for discovery of covalent inhibitors of target proteins. ACS Med Chem Lett. 13:1574–1581. 2022.PubMed/NCBI View Article : Google Scholar

Jensen JL, Mato AR, Pena C, Roeker LE and Coombs CC: The potential of pirtobrutinib in multiple B-cell malignancies. Ther Adv Hematol. 13(20406207221101697)2022.PubMed/NCBI View Article : Google Scholar

Hillmen P, Pitchford A, Bloor A, Broom A, Young M, Kennedy B, Walewska R, Furtado M, Preston G, Neilson JR, et al: Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): Interim analysis of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 24:535–552. 2023.PubMed/NCBI View Article : Google Scholar

Brown JR, Eichhorst B, Hillmen P, Jurczak W, Kaźmierczak M, Lamanna N, O'Brien SM, Tam CS, Qiu L, Zhou K, et al: Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 388:319–332. 2023.PubMed/NCBI View Article : Google Scholar

Hillmen P, Eichhorst B, Brown JR, Lamanna N, O'Brien SM, Tam CS, Qiu L, Kazmierczak M, Zhou K, Šimkovič M, et al: Zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: Interim analysis of a randomized phase III trial. J Clin Oncol. 41:1035–1045. 2023.PubMed/NCBI View Article : Google Scholar

Mato AR, Woyach JA, Brown JR, Ghia P, Patel K, Eyre TA, Munir T, Lech-Maranda E, Lamanna N, Tam CS, et al: Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia. N Engl J Med. 389:33–44. 2023.PubMed/NCBI View Article : Google Scholar

Gill S, Vides V, Frey NV, Hexner EO, Metzger S, O'Brien M, Hwang WT, Brogdon JL, Davis MM, Fraietta JA, et al: Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia. Blood Adv. 6:5774–5785. 2022.PubMed/NCBI View Article : Google Scholar

Ghia P, Pluta A, Wach M, Lysak D, Šimkovič M, Kriachok I, Illés Á, de la Serna J, Dolan S, Campbell P, et al: Acalabrutinib versus investigator's choice in relapsed/refractory chronic lymphocytic leukemia: Final ASCEND trial results. Hemasphere. 6(e801)2022.PubMed/NCBI View Article : Google Scholar

Nguyen TT, Nhu NT, Tran VK, Nguyen TTH and Lin CF: Efficacy and safety of Bruton tyrosine kinase inhibitor monotherapy compared with combination therapy for chronic lymphocytic leukemia and small lymphocytic lymphoma: A systematic review and meta-analysis. Cancers (Basel). 15(1996)2023.PubMed/NCBI View Article : Google Scholar

Lee P, Kistler KD, Douyon L, Volodarsky R, Young A, Karve S and Challagulla S: Systematic literature review of real-world effectiveness results data for first-line ibrutinib in chronic lymphocytic leukemia and small lymphocytic lymphoma. Drugs Real World Outcomes. 10:11–22. 2023.PubMed/NCBI View Article : Google Scholar

Boriani G, Menna P, Morgagni R, Minotti G and Vitolo M: Ibrutinib and Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia: focus on atrial fibrillation and ventricular tachyarrhythmias/sudden cardiac death. Chemotherapy. 68:61–72. 2023.PubMed/NCBI View Article : Google Scholar

Špaček M, Smolej L, Šimkovič M, Nekvindová L, Křístková Z, Brychtová Y, Panovská A, Mašlejová S, Bezděková L, Écsiová D, et al: Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real-world analysis from the chronic lymphocytic leukemia patients registry (CLLEAR). Br J Haematol. 202:40–47. 2023.PubMed/NCBI View Article : Google Scholar

Muhowski EM, Ravikrishnan J, Gordon B, Yu L, Misra S, Walker B, Eathiraj S, Sampath D, Rogers KA, Byrd JC and Woyach JA: Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia. J Hematol Oncol. 15(166)2022.PubMed/NCBI View Article : Google Scholar

Eyre TA and Riches JC: The evolution of therapies targeting Bruton tyrosine kinase for the treatment of chronic lymphocytic leukaemia: Future perspectives. Cancers (Basel). 15(2596)2023.PubMed/NCBI View Article : Google Scholar

Perutelli F, Montalbano MC, Boccellato E, Coscia M and Vitale C: Beyond ibrutinib: Novel BTK inhibitors for the treatment of chronic lymphocytic leukemia. Curr Opin Oncol. 34:757–767. 2022.PubMed/NCBI View Article : Google Scholar

Roeker LE, DerSarkissian M, Ryan K, Chen Y, Duh MS, Wahlstrom SK, Hakre S, Yu L, Guo H and Mato AR: Real-world comparative effectiveness of acalabrutinib and ibrutinib in patients with chronic lymphocytic leukemia. Blood Adv. 7:4291–4301. 2023.PubMed/NCBI View Article : Google Scholar

Munir T, Genovez V, Genestier V, Ryan K, Liljas B and Gaitonde P: Cost-effectiveness of acalabrutinib regimens in treatment-naïve chronic lymphocytic leukemia in the United States. Expert Rev Pharmacoecon Outcomes Res. 23:579–589. 2023.PubMed/NCBI View Article : Google Scholar

Wallace DS, Zent CS, Baran AM, Reagan PM, Casulo C, Rice G, Friedberg JW and Barr PM: Acalabrutinib and high-frequency low-dose subcutaneous rituximab for initial therapy of chronic lymphocytic leukemia. Blood Adv. 7:2496–2503. 2023.PubMed/NCBI View Article : Google Scholar

Podoll T, Pearson PG, Kaptein A, Evarts J, de Bruin G, Emmelot-van Hoek M, de Jong A, van Lith B, Sun H, Byard S, et al: Identification and characterization of ACP-5862, the major circulating active metabolite of acalabrutinib: Both are potent and selective covalent Bruton tyrosine kinase inhibitors. J Pharmacol Exp Ther. 384:173–186. 2023.PubMed/NCBI View Article : Google Scholar

Wolska-Washer A and Robak T: Zanubrutinib for the treatment of lymphoid malignancies: Current status and future directions. Front Oncol. 13(1130595)2023.PubMed/NCBI View Article : Google Scholar

Molica S, Tam C, Allsup D and Polliack A: Advancements in the treatment of CLL: The rise of zanubrutinib as a preferred therapeutic option. Cancers (Basel). 15(3737)2023.PubMed/NCBI View Article : Google Scholar

Gu D, Li J and Miao Y: Evaluating orelabrutinib as a novel treatment option for relapsed/refractory chronic lymphocytic leukemia in China. Expert Opin Pharmacother. 23:1979–1986. 2022.PubMed/NCBI View Article : Google Scholar

Robak P, Witkowska M, Wolska-Washer A and Robak T: The preclinical discovery and development of orelabrutinib as a novel treatment option for B-cell lymphoid malignancies. Expert Opin Drug Discov. 18:1065–1076. 2023.PubMed/NCBI View Article : Google Scholar

Munakata W, Ando K, Yokoyama M, Fukuhara N, Yamamoto K, Fukuhara S, Ohmachi K, Mishima Y, Ichikawa S, Ogiya D, et al: Long-term safety profile of tirabrutinib: final results of a Japanese phase I study in patients with relapsed or refractory B-cell malignancies. Int J Hematol. 117:553–562. 2023.PubMed/NCBI View Article : Google Scholar

Wang H, Guo H, Yang J, Liu Y, Liu X, Zhang Q and Zhou K: Bruton tyrosine kinase inhibitors in B-cell lymphoma: Beyond the antitumour effect. Exp Hematol Oncol. 11(60)2022.PubMed/NCBI View Article : Google Scholar

Yano M, Nunes J, Mo X, Rogers KA, Woyach JA, Byrd JC and Muthusamy N: Differential regulation of CTLA4 expression through BTK-dependent and independent mechanisms in CLL. Blood Adv. 6:5440–5448. 2022.PubMed/NCBI View Article : Google Scholar

Lee HK, Hoechstetter MA, Buchner M, Pham TT, Huh JW, Müller K, Zange S, von Buttlar H, Girl P, Wölfel R, et al: Analysis of immune responses in patients with CLL after heterologous COVID-19 vaccination. Blood Adv. 7:2214–2227. 2023.PubMed/NCBI View Article : Google Scholar

Daniel A, Ghez D, Ravaiau C, Cavalieri D, Tournilhac O, Herbaux C, Roriz M, Wemeau M, Guillet S, Bossard JB, et al: Ibrutinib as a treatment of hematologic autoimmune disorders in patients with indolent B-cell lymphoma. Eur J Haematol. 109:719–727. 2022.PubMed/NCBI View Article : Google Scholar

Yan Y, Lv R, Wang T, Yu Y, Huang Y, Xiong W, Li Y, Sui W, Wang Q, Huang W, et al: Real-world treatment patterns, discontinuation and clinical outcomes in patients with B-cell lymphoproliferative diseases treated with BTK inhibitors in China. Front Immunol. 14(1184395)2023.PubMed/NCBI View Article : Google Scholar

Sharma S, Pepin X, Burri H, Zheng L, Kuptsova-Clarkson N, de Jong A, Yu T, MacArthur HL, Majewski M, Byrd JC, et al: Bioequivalence and relative bioavailability studies to assess a new acalabrutinib formulation that enables coadministration with proton-pump inhibitors. Clin Pharmacol Drug Dev. 11:1294–1307. 2022.PubMed/NCBI View Article : Google Scholar

Karadeniz M, Cinar OE, Erdogdu B, Malkan UY, Goker H and Ozcebe OI: Hypophosphatemia related to the use of ibrutinib. J Oncol Pharm Pract: 10781552231164504, 2023 (Epub ahead of print).

Wan Q, Li Q, Lai X, Xu T, Hu J and Peng H: Data mining and safety analysis of BTK inhibitors: A pharmacovigilance investigation based on the FAERS database. Front Pharmacol. 13(995522)2022.PubMed/NCBI View Article : Google Scholar

Awan FT, Addison D, Alfraih F, Baratta SJ, Campos RN, Cugliari MS, Goh YT, Ionin VA, Mundnich S, Sverdlov AL, et al: International consensus statement on the management of cardiovascular risk of Bruton's tyrosine kinase inhibitors in CLL. Blood Adv. 6:5516–5525. 2022.PubMed/NCBI View Article : Google Scholar

Gordon MJ, Jones JE, George B, Peterson C, Burger JA, Jain N, Keating M, Wierda WG, Durand JB and Ferrajoli A: Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity. Cancer. 129:2192–2200. 2023.PubMed/NCBI View Article : Google Scholar

Seymour JF, Byrd JC, Ghia P, Kater AP, Chanan-Khan A, Furman RR, O'Brien S, Brown JR, Munir T, Mato A, et al: Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial. Blood. 142:687–699. 2023.PubMed/NCBI View Article : Google Scholar

Elaskalani O, Gilmore G, Hagger M, Baker RI and Metharom P: Adenosine 2A receptor activation amplifies ibrutinib antiplatelet effect; implications in chronic lymphocytic leukemia. Cancers (Basel). 14(5750)2022.PubMed/NCBI View Article : Google Scholar

Tham K, Prelewicz S, deHoll S, Stephens DM and Gomez CA: Infectious complications among patients receiving ibrutinib for the treatment of hematological malignancies. Am J Health Syst Pharm. 81:112–119. 2024.PubMed/NCBI View Article : Google Scholar

Diella L, Bavaro DF, Loseto G, Pasciolla C, Minoia C, Di Gennaro D, Belati A, De Candia MS, Di Gennaro F, Saracino A and Guarini A: Current therapies for chronic lymphocytic leukemia: Risk and prophylaxis strategies for secondary/opportunistic infections. Expert Rev Hematol. 16:267–276. 2023.PubMed/NCBI View Article : Google Scholar

No authors listed. Correction to: Managing ibrutinib-intolerant patients with B-cell malignancies. Oncologist. 28(e487)2023.PubMed/NCBI View Article : Google Scholar

Shadman M, Flinn IW, Levy MY, Porter RF, Burke JM, Zafar SF, Misleh J, Kingsley EC, Yimer HA, Freeman B, et al: Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: A phase 2, open-label, single-arm study. Lancet Haematol. 10:e35–e45. 2023.PubMed/NCBI View Article : Google Scholar

Salmerón-Navas FJ, Barreiro-Fernández EM and Fénix-Caballero S: Adjusted indirect comparison of zanubrutinib and ibrutinib in first-line treatment of chronic lymphocytic leukemia. Farm Hosp. 48:9–15. 2024.PubMed/NCBI View Article : Google Scholar

Chen S, Wei Y, Li S, Miao Y, Gu J, Cui Y, Liu Z, Liang J, Wei L, Li X, et al: Zanubrutinib attenuates bleomycin-induced pulmonary fibrosis by inhibiting the TGF-β1 signaling pathway. Int Immunopharmacol. 113(109316)2022.PubMed/NCBI View Article : Google Scholar

Blombery P, Thompson ER, Lew TE, Tiong IS, Bennett R, Cheah CY, Lewis KL, Handunnetti SM, Tang CPS, Roberts A, et al: Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: Potential for pirtobrutinib cross-resistance. Blood Adv. 6:5589–5592. 2022.PubMed/NCBI View Article : Google Scholar

Naeem A, Utro F, Wang Q, Cha J, Vihinen M, Martindale S, Zhou Y, Ren Y, Tyekucheva S, Kim AS, et al: Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance. Blood Adv. 7:1929–1943. 2023.PubMed/NCBI View Article : Google Scholar

Takács F, Kotmayer L, Czeti Á, Szalóki G, László T, Mikala G, Márk Á, Masszi A, Farkas P, Plander M, et al: Revealing a phenotypical appearance of ibrutinib resistance in patients with chronic lymphocytic leukaemia by flow cytometry. Pathol Oncol Res. 28(1610659)2022.PubMed/NCBI View Article : Google Scholar

Maher N, Mouhssine S, Matti BF, Alwan AF and Gaidano G: Treatment refractoriness in chronic lymphocytic leukemia: Old and new molecular biomarkers. Int J Mol Sci. 24(10374)2023.PubMed/NCBI View Article : Google Scholar

Woyach JA, Ghia P, Byrd JC, Ahn IE, Moreno C, O'Brien SM, Jones D, Cheung LWK, Chong E, Kwei K, et al: B-cell receptor pathway mutations are infrequent in patients with chronic lymphocytic leukemia on continuous ibrutinib therapy. Clin Cancer Res. 29:3065–3073. 2023.PubMed/NCBI View Article : Google Scholar

Alsadhan A, Chen J, Gaglione EM, Underbayev C, Tuma PL, Tian X, Freeman LA, Baskar S, Nierman P, Soto S, et al: CD49d expression identifies a biologically distinct subtype of chronic lymphocytic leukemia with inferior progression-free survival on BTK inhibitor therapy. Clin Cancer Res. 29:3612–3621. 2023.PubMed/NCBI View Article : Google Scholar

Tissino E, Bomben R, Gattei V and Zucchetto A: BCR/integrin interaction in CLL: A physiologic remnant with clinical relevance. Clin Cancer Res. 29:3560–3562. 2023.PubMed/NCBI View Article : Google Scholar

Thompson PA and Tam CS: Pirtobrutinib: A new hope for patients with BTK inhibitor-refractory lymphoproliferative disorders. Blood. 141:3137–3142. 2023.PubMed/NCBI View Article : Google Scholar

Chung C, Umoru G, Abboud K and Hobaugh E: Sequencing and combination of current small-molecule inhibitors for chronic lymphocytic leukemia: Where is the evidence? Eur J Haematol. 111:15–28. 2023.PubMed/NCBI View Article : Google Scholar

Rizzuto A, Pirrera A, Gigliotta E, Mancuso S, Vullo C, Camarda GM, Rotolo C, Roppolo A, Spoto C, Gentile M, et al: Molecular-biology-driven frontline treatment for chronic lymphocytic leukemia: A network meta-analysis of randomized clinical trials. Int J Mol Sci. 24(9930)2023.PubMed/NCBI View Article : Google Scholar

Nguyen TT, Thanh Nhu N, Tran VK, Van Cau N and Lin CF: Efficacy and safety of Bruton tyrosine kinase inhibitor plus anti-CD20 antibody therapy compared with chemoimmunotherapy as front-line treatment for chronic lymphocytic leukemia: A systematic review and meta-analysis of randomized controlled trials. J Immunother. 46:299–309. 2023.PubMed/NCBI View Article : Google Scholar

Nguyen TT, Nhu NT, Tran VK, Viet-Nhi NK, Ho XD, Jhan MK, Chen YP and Lin CF: Efficacy and safety of add-on anti-CD20 monoclonal antibody to Bruton tyrosine kinase inhibitor treatment for chronic lymphocytic leukemia: A meta-analysis. Sci Rep. 13(9775)2023.PubMed/NCBI View Article : Google Scholar

Scarfò L, Heltai S, Albi E, Scarano E, Schiattone L, Farina L, Moia R, Deodato M, Ferrario A, Motta M, et al: Minimal residual disease-driven treatment intensification with sequential addition of ibrutinib to venetoclax in R/R CLL. Blood. 140:2348–2357. 2022.PubMed/NCBI View Article : Google Scholar

Cervantes-Gomez F, Lamothe B, Woyach JA, Wierda WG, Keating MJ, Balakrishnan K and Gandhi V: Pharmacological and protein profiling suggests venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic leukemia. Clin Cancer Res. 21:3705–3715. 2015.PubMed/NCBI View Article : Google Scholar

Godwin CD, Bates OM, Garling EE, Beddoe ME, Laszlo GS and Walter RB: The Bruton's tyrosine kinase inhibitor ibrutinib abrogates bispecific antibody-mediated T-cell cytotoxicity. Br J Haematol. 189:e9–e13. 2020.PubMed/NCBI View Article : Google Scholar

Mhibik M, Gaglione EM, Eik D, Kendall EK, Blackburn A, Keyvanfar K, Baptista MJ, Ahn IE, Sun C, Qi J, et al: BTK inhibitors, irrespective of ITK inhibition, increase efficacy of a CD19/CD3-bispecific antibody in CLL. Blood. 138:1843–1854. 2012.PubMed/NCBI View Article : Google Scholar

Nasnas P, Cerchione C, Musuraca G, Martinelli G and Ferrajoli A: How I manage chronic lymphocytic leukemia. Hematol Rep. 15:454–464. 2023.PubMed/NCBI View Article : Google Scholar

Easaw S, Ezzati S and Coombs CC: SOHO State of the art updates and next questions: Updates on BTK inhibitors for the treatment of chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 23:697–704. 2023.PubMed/NCBI View Article : Google Scholar

Kim T, Kim K, Park I, Hong S and Park H: Two-track virtual screening approach to identify the dual inhibitors of wild type and C481S mutant of Bruton's tyrosine kinase. J Chem Inf Model. 62:4500–4511. 2022.PubMed/NCBI View Article : Google Scholar

Thus YJ, De Rooij MFM, Beijersbergen RL and Spaargaren M: An Unbiased CRISPR-Cas9 screening method for the identification of positive and negative regulatory proteins of cell adhesion. Bio Protoc. 12(e4545)2022.PubMed/NCBI View Article : Google Scholar

Mihăilă RG and Topîrcean D: The high-performance technology CRISPR/Cas9 improves knowledge and management of acute myeloid leukemia. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 165:249–257. 2021.PubMed/NCBI View Article : Google Scholar

Sampietro M, Cassina V, Salerno D, Barbaglio F, Buglione E, Marrano CA, Campanile R, Scarfò L, Biedenweg D, Fregin B, et al: The nanomechanical properties of CLL cells are linked to the actin cytoskeleton and are a potential target of BTK inhibitors. Hemasphere. 7(e931)2023.PubMed/NCBI View Article : Google Scholar